The Quantellect read.As of Nov 19, 2026, 10 active firms cover West Pharmaceutical Services Inc: 10 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $360.00 to $447.00, so the covering firms are broadly aligned. The average target of $412.11 sits 2% above the current $404.00. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.35 next quarter toward $10.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy10100%
Neutral00%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$412.11
+2.0% upside
Average target across 9 active firms as of Nov 19, 2026 vs $404.00 current
Highest Target$447.00
Average Target$412.11
Lowest Target$360.00
Detailed analyst forecasts for WST
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 10 of 10 active firms rate WST a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
WST EPS & revenue forecast
EPS · NEXT QUARTER
$2.35
Range $2.31 – $2.40 · 6 analysts · +10% YoY
Next period, 6 analysts expect West Pharmaceutical Services Inc to earn $2.35 a share (range $2.31 – $2.40), versus $2.13 a year earlier. Full-year consensus is $9.46, growing to $10.39 the year after.
REVENUE · NEXT QUARTER
$859.2M
Range $834.9M – $895.9M · 6 analysts · +2% YoY
Revenue is expected to reach $859.2M (range $834.9M – $895.9M), +1.7% year-over-year. Full-year consensus is $3.4B, rising to $3.6B next year.
Top analysts covering West Pharmaceutical Services Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on WST.
#1
Joanne Wuensch
Citigroup · Rank #35
Buy
$412.00+2.0% to target
Overall win rate
51%
+ Follow
#2
Luke Sergott
Barclays · Rank #267
Buy
$440.00+8.9% to target
Overall win rate
43%
+ Follow
#3
Vijay Kumar
Evercore ISI Group · Rank #331
Buy
No targeton WST
Overall win rate
36%
+ Follow
#4
Paul Knight
Keybanc · Rank #394
Buy
$390.00-3.5% to target
Overall win rate
39%
+ Follow
#5
Patrick Donnelly
Citigroup · Rank #448
Buy
$400.00-1.0% to target
Overall win rate
29%
+ Follow
WST stock forecast FAQ
What is WST's average 12-month price target?+
The 9 active firms with a live target average $412.11 for West Pharmaceutical Services Inc over the next 12 months, ranging from a $447.00 high to a $360.00 low, as of Nov 19, 2026.
Is WST stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for WST?+
The Street-high target is $447.00 (BNP Paribas), and the Street-low is $360.00 (Stephens & Co.). The average of all 9 active-firm targets is $412.11.
How many active Wall Street firms cover WST?+
10 active firms have a recognized rating on West Pharmaceutical Services Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering WST?+
Among analysts who currently cover WST, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $412.00 target.
What is West Pharmaceutical Services Inc's projected EPS for next quarter?+
The consensus estimate is $2.35 per share (range $2.31 – $2.40) across 6 analysts. Full-year EPS is projected at $9.46, rising to $10.39 the following year.
How much revenue is West Pharmaceutical Services Inc expected to report next quarter?+
Consensus revenue is $859.2M (range $834.9M – $895.9M). Full-year revenue is projected at $3.4B, growing to $3.6B next year.
Have analysts been upgrading or downgrading WST lately?+
As of Nov 19, 2026, 10 of 10 active firms rate WST a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their WST calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.